SEMA4D and metabolic syndrome: A few studies have been performed to establish a possible role for CD100 in the development of atherosclerosis in the mice model; they have shown that lack of Sema4D reduces platelet hyperactivity otherwise found in dyslipidemia, thus conferring protection against atherosclerosis [15].